TransMedics Group, Inc. $TMDX Position Trimmed by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 57.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 398,250 shares of the company’s stock after selling 541,273 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in TransMedics Group were worth $26,452,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of TMDX. Silvant Capital Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth $26,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of TransMedics Group during the third quarter valued at $29,000. North Star Investment Management Corp. purchased a new stake in shares of TransMedics Group during the first quarter valued at $30,000. Ascentis Independent Advisors acquired a new position in shares of TransMedics Group in the 1st quarter valued at $30,000. Finally, Allworth Financial LP increased its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 3.2%

NASDAQ:TMDX opened at $86.98 on Friday. The stock has a market cap of $3.01 billion, a PE ratio of 22.36 and a beta of 1.90. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The stock’s 50-day moving average is $79.71 and its two-hundred day moving average is $92.23.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The company had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. During the same period last year, the company earned $0.92 earnings per share. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the topic of several recent analyst reports. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Wall Street Zen downgraded shares of TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Stifel Nicolaus boosted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Finally, Piper Sandler reissued an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, TransMedics Group presently has an average rating of “Hold” and an average price target of $124.18.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.